nodes	percent_of_prediction	percent_of_DWPC	metapath
Tadalafil—PDE5A—clitoris—polycystic ovary syndrome	0.252	0.704	CbGeAlD
Tadalafil—Angina unstable—Metformin—polycystic ovary syndrome	0.0342	0.102	CcSEcCtD
Tadalafil—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.0331	0.0987	CcSEcCtD
Tadalafil—PDE11A—cGMP effects—PDE3B—polycystic ovary syndrome	0.0312	0.102	CbGpPWpGaD
Tadalafil—PDE5A—cGMP effects—PDE3B—polycystic ovary syndrome	0.0278	0.0907	CbGpPWpGaD
Tadalafil—PDE11A—Nitric oxide stimulates guanylate cyclase—PDE3B—polycystic ovary syndrome	0.0248	0.0808	CbGpPWpGaD
Tadalafil—PDE11A—adrenal gland—polycystic ovary syndrome	0.0239	0.0667	CbGeAlD
Tadalafil—PDE5A—Nitric oxide stimulates guanylate cyclase—PDE3B—polycystic ovary syndrome	0.0221	0.0721	CbGpPWpGaD
Tadalafil—PDE11A—endocrine gland—polycystic ovary syndrome	0.0207	0.0579	CbGeAlD
Tadalafil—Sinus congestion—Metformin—polycystic ovary syndrome	0.0174	0.0518	CcSEcCtD
Tadalafil—Loose stools—Metformin—polycystic ovary syndrome	0.0156	0.0465	CcSEcCtD
Tadalafil—CYP3A4—urine—polycystic ovary syndrome	0.0148	0.0414	CbGeAlD
Tadalafil—Upset stomach—Metformin—polycystic ovary syndrome	0.0132	0.0393	CcSEcCtD
Tadalafil—PDE5A—adipose tissue—polycystic ovary syndrome	0.0101	0.0283	CbGeAlD
Tadalafil—PDE11A—Platelet homeostasis—PDE3B—polycystic ovary syndrome	0.00966	0.0315	CbGpPWpGaD
Tadalafil—PDE5A—adrenal gland—polycystic ovary syndrome	0.00908	0.0254	CbGeAlD
Tadalafil—PDE5A—Platelet homeostasis—PDE3B—polycystic ovary syndrome	0.00861	0.0281	CbGpPWpGaD
Tadalafil—PDE5A—female gonad—polycystic ovary syndrome	0.00846	0.0237	CbGeAlD
Tadalafil—PDE5A—vagina—polycystic ovary syndrome	0.00841	0.0235	CbGeAlD
Tadalafil—PDE11A—G alpha (s) signalling events—LHCGR—polycystic ovary syndrome	0.0083	0.027	CbGpPWpGaD
Tadalafil—PDE5A—endocrine gland—polycystic ovary syndrome	0.00787	0.022	CbGeAlD
Tadalafil—Nasal congestion—Metformin—polycystic ovary syndrome	0.00689	0.0205	CcSEcCtD
Tadalafil—PDE11A—G alpha (s) signalling events—PDE3B—polycystic ovary syndrome	0.00667	0.0217	CbGpPWpGaD
Tadalafil—Renal impairment—Metformin—polycystic ovary syndrome	0.00659	0.0196	CcSEcCtD
Tadalafil—Pain in extremity—Metformin—polycystic ovary syndrome	0.00627	0.0187	CcSEcCtD
Tadalafil—Migraine—Metformin—polycystic ovary syndrome	0.00617	0.0184	CcSEcCtD
Tadalafil—CYP3A4—Benzo(a)pyrene metabolism—AKR1C2—polycystic ovary syndrome	0.00613	0.02	CbGpPWpGaD
Tadalafil—PDE11A—G alpha (s) signalling events—FSHR—polycystic ovary syndrome	0.00607	0.0198	CbGpPWpGaD
Tadalafil—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00579	0.0173	CcSEcCtD
Tadalafil—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00573	0.0171	CcSEcCtD
Tadalafil—Breast disorder—Metformin—polycystic ovary syndrome	0.00567	0.0169	CcSEcCtD
Tadalafil—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00561	0.0167	CcSEcCtD
Tadalafil—Influenza—Metformin—polycystic ovary syndrome	0.00542	0.0162	CcSEcCtD
Tadalafil—PDE11A—G alpha (s) signalling events—ADRB3—polycystic ovary syndrome	0.00535	0.0174	CbGpPWpGaD
Tadalafil—PDE11A—G alpha (s) signalling events—LHB—polycystic ovary syndrome	0.00528	0.0172	CbGpPWpGaD
Tadalafil—Angina pectoris—Metformin—polycystic ovary syndrome	0.00528	0.0157	CcSEcCtD
Tadalafil—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.0052	0.0155	CcSEcCtD
Tadalafil—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00504	0.015	CcSEcCtD
Tadalafil—PDE11A—G alpha (s) signalling events—SCT—polycystic ovary syndrome	0.00495	0.0161	CbGpPWpGaD
Tadalafil—Infestation NOS—Metformin—polycystic ovary syndrome	0.00483	0.0144	CcSEcCtD
Tadalafil—Infestation—Metformin—polycystic ovary syndrome	0.00483	0.0144	CcSEcCtD
Tadalafil—Rhinitis—Metformin—polycystic ovary syndrome	0.00435	0.013	CcSEcCtD
Tadalafil—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00432	0.0129	CcSEcCtD
Tadalafil—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00428	0.0127	CcSEcCtD
Tadalafil—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00426	0.0127	CcSEcCtD
Tadalafil—Eye disorder—Metformin—polycystic ovary syndrome	0.00406	0.0121	CcSEcCtD
Tadalafil—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00403	0.012	CcSEcCtD
Tadalafil—Flushing—Metformin—polycystic ovary syndrome	0.00403	0.012	CcSEcCtD
Tadalafil—Angiopathy—Metformin—polycystic ovary syndrome	0.00394	0.0117	CcSEcCtD
Tadalafil—Immune system disorder—Metformin—polycystic ovary syndrome	0.00392	0.0117	CcSEcCtD
Tadalafil—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00391	0.0117	CcSEcCtD
Tadalafil—PDE11A—Platelet homeostasis—GNAS—polycystic ovary syndrome	0.00388	0.0126	CbGpPWpGaD
Tadalafil—Muscle spasms—Metformin—polycystic ovary syndrome	0.00363	0.0108	CcSEcCtD
Tadalafil—Vision blurred—Metformin—polycystic ovary syndrome	0.00356	0.0106	CcSEcCtD
Tadalafil—PDE5A—Platelet homeostasis—GNAS—polycystic ovary syndrome	0.00346	0.0113	CbGpPWpGaD
Tadalafil—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—polycystic ovary syndrome	0.00341	0.0111	CbGpPWpGaD
Tadalafil—Syncope—Metformin—polycystic ovary syndrome	0.00339	0.0101	CcSEcCtD
Tadalafil—Palpitations—Metformin—polycystic ovary syndrome	0.00334	0.00995	CcSEcCtD
Tadalafil—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00332	0.00989	CcSEcCtD
Tadalafil—Hypertension—Metformin—polycystic ovary syndrome	0.00326	0.00972	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—GP1BB—polycystic ovary syndrome	0.00323	0.0105	CbGpPWpGaD
Tadalafil—Myalgia—Metformin—polycystic ovary syndrome	0.00322	0.00958	CcSEcCtD
Tadalafil—Chest pain—Metformin—polycystic ovary syndrome	0.00322	0.00958	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00319	0.00952	CcSEcCtD
Tadalafil—Discomfort—Metformin—polycystic ovary syndrome	0.00318	0.00947	CcSEcCtD
Tadalafil—Oedema—Metformin—polycystic ovary syndrome	0.00308	0.00919	CcSEcCtD
Tadalafil—Infection—Metformin—polycystic ovary syndrome	0.00306	0.00913	CcSEcCtD
Tadalafil—Shock—Metformin—polycystic ovary syndrome	0.00303	0.00904	CcSEcCtD
Tadalafil—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00302	0.00901	CcSEcCtD
Tadalafil—Skin disorder—Metformin—polycystic ovary syndrome	0.00299	0.00892	CcSEcCtD
Tadalafil—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00298	0.00888	CcSEcCtD
Tadalafil—PDE11A—G alpha (s) signalling events—ADRB2—polycystic ovary syndrome	0.00289	0.00941	CbGpPWpGaD
Tadalafil—Hypotension—Metformin—polycystic ovary syndrome	0.00288	0.00859	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—GP1BB—polycystic ovary syndrome	0.00288	0.00938	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00281	0.00837	CcSEcCtD
Tadalafil—Paraesthesia—Metformin—polycystic ovary syndrome	0.00277	0.00825	CcSEcCtD
Tadalafil—Dyspnoea—Metformin—polycystic ovary syndrome	0.00275	0.00819	CcSEcCtD
Tadalafil—Somnolence—Metformin—polycystic ovary syndrome	0.00274	0.00817	CcSEcCtD
Tadalafil—Dyspepsia—Metformin—polycystic ovary syndrome	0.00271	0.00809	CcSEcCtD
Tadalafil—PDE11A—G alpha (s) signalling events—GNAS—polycystic ovary syndrome	0.00268	0.00873	CbGpPWpGaD
Tadalafil—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00266	0.00793	CcSEcCtD
Tadalafil—Fatigue—Metformin—polycystic ovary syndrome	0.00266	0.00792	CcSEcCtD
Tadalafil—Constipation—Metformin—polycystic ovary syndrome	0.00264	0.00786	CcSEcCtD
Tadalafil—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—polycystic ovary syndrome	0.00263	0.00856	CbGpPWpGaD
Tadalafil—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00252	0.00751	CcSEcCtD
Tadalafil—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00245	0.00686	CbGeAlD
Tadalafil—Urticaria—Metformin—polycystic ovary syndrome	0.00245	0.0073	CcSEcCtD
Tadalafil—Abdominal pain—Metformin—polycystic ovary syndrome	0.00244	0.00726	CcSEcCtD
Tadalafil—Asthenia—Metformin—polycystic ovary syndrome	0.00221	0.00659	CcSEcCtD
Tadalafil—Pruritus—Metformin—polycystic ovary syndrome	0.00218	0.0065	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—PDE3B—polycystic ovary syndrome	0.00217	0.00706	CbGpPWpGaD
Tadalafil—Diarrhoea—Metformin—polycystic ovary syndrome	0.00211	0.00629	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00204	0.00665	CbGpPWpGaD
Tadalafil—Dizziness—Metformin—polycystic ovary syndrome	0.00204	0.00608	CcSEcCtD
Tadalafil—Vomiting—Metformin—polycystic ovary syndrome	0.00196	0.00584	CcSEcCtD
Tadalafil—Rash—Metformin—polycystic ovary syndrome	0.00194	0.00579	CcSEcCtD
Tadalafil—Dermatitis—Metformin—polycystic ovary syndrome	0.00194	0.00579	CcSEcCtD
Tadalafil—Headache—Metformin—polycystic ovary syndrome	0.00193	0.00576	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—PDE3B—polycystic ovary syndrome	0.00193	0.00629	CbGpPWpGaD
Tadalafil—CYP3A4—Drug Induction of Bile Acid Pathway—SULT2A1—polycystic ovary syndrome	0.00189	0.00615	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—RACGAP1—polycystic ovary syndrome	0.00185	0.00604	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00185	0.00604	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00184	0.00601	CbGpPWpGaD
Tadalafil—Nausea—Metformin—polycystic ovary syndrome	0.00183	0.00546	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00181	0.00589	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00181	0.00589	CbGpPWpGaD
Tadalafil—PDE11A—G alpha (s) signalling events—POMC—polycystic ovary syndrome	0.0018	0.00588	CbGpPWpGaD
Tadalafil—CYP3A4—Farnesoid X Receptor  Pathway—SULT2A1—polycystic ovary syndrome	0.00173	0.00563	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.0017	0.00555	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.0017	0.00555	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00168	0.00546	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—RACGAP1—polycystic ovary syndrome	0.00165	0.00538	CbGpPWpGaD
Tadalafil—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—polycystic ovary syndrome	0.00165	0.00537	CbGpPWpGaD
Tadalafil—CYP3A4—Tamoxifen metabolism—SULT2A1—polycystic ovary syndrome	0.00159	0.00519	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00159	0.00519	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00155	0.00504	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00155	0.00504	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00155	0.00504	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.0015	0.0049	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00145	0.00471	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.0014	0.00458	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00137	0.00446	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00137	0.00445	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00125	0.00408	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00125	0.00406	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00124	0.00405	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00114	0.00371	CbGpPWpGaD
Tadalafil—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—polycystic ovary syndrome	0.00114	0.00371	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PLAT—polycystic ovary syndrome	0.00113	0.00369	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00113	0.00369	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.0011	0.00358	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NPB—polycystic ovary syndrome	0.00109	0.00357	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00108	0.00353	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00106	0.00345	CbGpPWpGaD
Tadalafil—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—polycystic ovary syndrome	0.00104	0.00339	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00104	0.00337	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00102	0.00331	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PLAT—polycystic ovary syndrome	0.00101	0.00329	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000996	0.00325	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00099	0.00323	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000985	0.00321	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000969	0.00316	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000962	0.00314	CbGpPWpGaD
Tadalafil—CYP3A4—Estrogen metabolism—CYP1A1—polycystic ovary syndrome	0.000947	0.00309	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000923	0.00301	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000913	0.00298	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000913	0.00298	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00088	0.00287	CbGpPWpGaD
Tadalafil—CYP3A4—Xenobiotics—CYP1A1—polycystic ovary syndrome	0.00087	0.00284	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—GNAS—polycystic ovary syndrome	0.000869	0.00283	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000854	0.00278	CbGpPWpGaD
Tadalafil—CYP3A4—Tamoxifen metabolism—CYP1A1—polycystic ovary syndrome	0.000837	0.00273	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000829	0.0027	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000807	0.00263	CbGpPWpGaD
Tadalafil—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—polycystic ovary syndrome	0.000804	0.00262	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000786	0.00256	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—GNAS—polycystic ovary syndrome	0.000775	0.00252	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000734	0.00239	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000716	0.00233	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000669	0.00218	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00065	0.00212	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000629	0.00205	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000611	0.00199	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—polycystic ovary syndrome	0.000609	0.00199	CbGpPWpGaD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—polycystic ovary syndrome	0.000601	0.00196	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FST—polycystic ovary syndrome	0.000596	0.00194	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000592	0.00193	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000589	0.00192	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LHB—polycystic ovary syndrome	0.000582	0.0019	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—AKR1C2—polycystic ovary syndrome	0.000571	0.00186	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000568	0.00185	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—polycystic ovary syndrome	0.000567	0.00185	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IGF1—polycystic ovary syndrome	0.000563	0.00183	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—AKT2—polycystic ovary syndrome	0.000563	0.00183	CbGpPWpGaD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—polycystic ovary syndrome	0.000559	0.00182	CbGpPWpGaD
Tadalafil—CYP3A4—Tryptophan metabolism—CYP19A1—polycystic ovary syndrome	0.000555	0.00181	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000551	0.00179	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000549	0.00179	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SCT—polycystic ovary syndrome	0.000545	0.00178	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000538	0.00175	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—SERPINE1—polycystic ovary syndrome	0.000535	0.00174	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.00052	0.00169	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000511	0.00166	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000507	0.00165	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—IGF1—polycystic ovary syndrome	0.000502	0.00164	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—AKT2—polycystic ovary syndrome	0.000501	0.00163	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000499	0.00163	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.000494	0.00161	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—SERPINE1—polycystic ovary syndrome	0.000477	0.00155	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000473	0.00154	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000467	0.00152	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.000459	0.0015	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.000448	0.00146	CbGpPWpGaD
Tadalafil—CYP3A4—Tryptophan metabolism—CYP1A1—polycystic ovary syndrome	0.000447	0.00146	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—INSR—polycystic ovary syndrome	0.000446	0.00145	CbGpPWpGaD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.000443	0.00144	CbGpPWpGaD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.00043	0.0014	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000424	0.00138	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000417	0.00136	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PGR—polycystic ovary syndrome	0.000413	0.00135	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000384	0.00125	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000384	0.00125	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.00037	0.00121	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—VEGFA—polycystic ovary syndrome	0.000368	0.0012	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000366	0.00119	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000364	0.00118	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000361	0.00118	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000357	0.00116	CbGpPWpGaD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000357	0.00116	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000356	0.00116	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000338	0.0011	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000336	0.00109	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PRL—polycystic ovary syndrome	0.000335	0.00109	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—VEGFA—polycystic ovary syndrome	0.000328	0.00107	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000323	0.00105	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000318	0.00104	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000318	0.00103	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.000296	0.000966	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000295	0.00096	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.000293	0.000955	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.000292	0.000952	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000281	0.000915	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000276	0.000898	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.000269	0.000878	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.000262	0.000855	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.000259	0.000843	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.000244	0.000797	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.000244	0.000795	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.000241	0.000784	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000236	0.000769	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LEP—polycystic ovary syndrome	0.000231	0.000753	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.000218	0.000712	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000206	0.000671	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—POMC—polycystic ovary syndrome	0.000198	0.000647	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—INS—polycystic ovary syndrome	0.000197	0.000643	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000193	0.000629	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000191	0.000622	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000191	0.000622	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.00019	0.000621	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000181	0.000591	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000156	0.000507	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000154	0.0005	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000146	0.000476	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	0.000137	0.000446	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	0.000125	0.000408	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	0.000125	0.000408	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000125	0.000406	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	0.000116	0.000379	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	0.000116	0.000378	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	9.9e-05	0.000323	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	9.9e-05	0.000323	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL6—polycystic ovary syndrome	8.62e-05	0.000281	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	8.29e-05	0.00027	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	7.86e-05	0.000256	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	7.5e-05	0.000244	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	6.69e-05	0.000218	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	6.38e-05	0.000208	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	5.82e-05	0.00019	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	5.68e-05	0.000185	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	5.51e-05	0.000179	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	5.07e-05	0.000165	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	4.91e-05	0.00016	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.73e-05	0.000154	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	4.54e-05	0.000148	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	4.49e-05	0.000146	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	4.24e-05	0.000138	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	4.17e-05	0.000136	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.61e-05	0.000118	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.51e-05	0.000114	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	3.3e-05	0.000108	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.95e-05	9.6e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.81e-05	9.15e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.66e-05	8.67e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.48e-05	8.09e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	2.01e-05	6.56e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.98e-05	6.47e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.97e-05	6.43e-05	CbGpPWpGaD
